In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

Kate Shemirani's sons tell the BBC news program 'Panorama' that her views discouraged their sister from seeking chemotherapy ...

THE daughter of an anti-vaxxer conspiracy theorist nurse died of blood cancer after listening to her and refusing treatment, ...

Dylan Williams (14) is currently in his third week of chemotherapy and lumbar punctures after being diagnosed with ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

WHAT kind of parent potentially sacrifices their child’s health on the altar of their own, ill-informed beliefs? Step forward ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

Yet there’s a major hurdle: Less than 1 % of U.S. farmland is USDA-certified organic, even though consumer demand for organic ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...